. Author manuscript; available in PMC: 2006 Apr 27.

Published in final edited form as: Oncogene. 2006 Apr 27;25(18):2636–2645. doi: 10.1038/sj.onc.1209145

Table 2.

Relative DNMT mRNA levels in ovarian epithelial borderline cancers vs. carcinomas^a

	LMP tumors	Carcinomas	P-value^b
DNMT1	1.2	0.8	0.25
DNMT2	1.4	0.6	<0.005^c
DNMT3A1^c	1.3	0.7	<0.005^c
DNMT3A2^c	1.1	0.9	0.64
DNMT3A (all isoforms)^c	1.2	0.8	0.07
DNMT3B1	1.1	1.0	0.34
DNMT3B1/3B2	0.3	1.7	0.005^c
DNMT3B3	0.9	1.1	0.35
DNMT3B4	0.9	1.2	0.27
DNMT3B5	0.6	1.5	0.29
DNMT3B (all isoforms)	0.9	1.1	0.42
DNMT3L	1.8^e	0.2^e	0.97^e

The mean reference gene-normalized DNMT RNA levels for 17 ovarian epithelial LMP tumors (borderline cancers) or 17 carcinomas are shown relative to the average expression level of all of these tumors.

The P-value for a significant difference between carcinomas and LMP tumors is given (Wilcoxon rank-sum test).

These RNAs showed statistically significant differences with the cut-point for significance set such that the overall rate of false discovery was 5%.

For clarity, we have used the term DNMT3A1 to denote the isoform initially referred to as DNMT3A (Chen et al., 2002). DNMT3A1 and DNMT3A2 isoforms have the same catalytic domains but differ in their N terminal domains. DNMT3A1 mRNA, the longer transcript, contains exons 1 through 6 and 8 through 24, whereas DNMT3A2 mRNA, the shorter transcript, contains two unique exons, 7α and 7ß, and exons 8 through 24. The reaction indicated by “all isoforms” covers exons 19 and 20, which are present in both DNMT3A isoforms.

Only two of the tumors showed appreciable RT-PCR product for DNMT3L.